Sectoral Asset Management Inc Denali Therapeutics Inc. Transaction History

Sectoral Asset Management Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$15.83 - $23.35 $12,664 - $18,680	-800 Reduced 6.21%	12,081 $247,000
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $3.92 Million - $5.61 Million	-242,060 Reduced 94.95%	12,881 $276,000
Q3 2023 Nov 14, 2023	BUY	$20.63 - $30.17 $199,079 - $291,140	9,650 Added 3.93%	254,941 $5.26 Million
Q2 2023 Aug 11, 2023	BUY	$23.37 - $32.96 $10,306 - $14,535	441 Added 0.18%	245,291 $7.24 Million
Q1 2023 May 12, 2023	BUY	$21.91 - $32.67 $21,910 - $32,670	1,000 Added 0.41%	244,850 $5.64 Million
Q4 2022 Feb 10, 2023	BUY	$26.28 - $33.92 $13,140 - $16,960	500 Added 0.21%	243,850 $6.78 Million
Q3 2022 Nov 10, 2022	BUY	$25.97 - $38.53 $1.07 Million - $1.59 Million	41,250 Added 20.41%	243,350 $7.47 Million
Q2 2022 Aug 15, 2022	SELL	$20.88 - $35.19 $104,400 - $175,950	-5,000 Reduced 2.41%	202,100 $5.95 Million
Q1 2022 May 10, 2022	BUY	$29.0 - $47.27 $507,500 - $827,225	17,500 Added 9.23%	207,100 $6.66 Million
Q4 2021 Feb 11, 2022	BUY	$42.59 - $55.02 $2.64 Million - $3.42 Million	62,100 Added 48.71%	189,600 $8.46 Million
Q3 2021 Nov 15, 2021	BUY	$48.48 - $78.23 $3.03 Million - $4.89 Million	62,500 Added 96.15%	127,500 $6.43 Million
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $3.07 Million - $4.78 Million	61,000 Added 1525.0%	65,000 $5.1 Million
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $215,200 - $326,120	4,000 New	4,000 $228,000
Q3 2020 Nov 13, 2020	SELL	$23.13 - $38.84 $222,048 - $372,864	-9,600 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$16.01 - $28.82 $153,696 - $276,672	9,600 New	9,600 $232,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Sectoral Asset Management Inc with notifications on news.